Name: rs8099917
Published: September 3, 2024
License: Open Access

Welcome to the Reference SNP (rs) Report

All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.

Reference SNP (rs) Report

This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.

rs8099917

Current Build 157

Released September 3, 2024

Organism: Homo sapiens
Position: chr19:39252525 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
Alleles: T>G
Variation Type: SNV Single Nucleotide Variation
Frequency: G=0.191184 (68297/357232, ALFA)
G=0.164683 (43590/264690, TOPMED)
G=0.155826 (23248/149192, GnomAD_genomes) (+ 21 more)
G=0.14906 (11731/78700, PAGE_STUDY)
G=0.09921 (7683/77444, 38KJPN)
G=0.0594 (430/7234, Korea4K)
G=0.1352 (866/6404, 1000G_30X)
G=0.1312 (657/5008, 1000G)
G=0.2054 (920/4480, Estonian)
G=0.1943 (749/3854, ALSPAC)
G=0.2009 (745/3708, TWINSUK)
G=0.0519 (152/2930, KOREAN)
G=0.1665 (347/2084, HGDP_Stanford)
G=0.1196 (226/1890, HapMap)
G=0.198 (198/998, GoNL)
G=0.275 (172/626, Chileans)
G=0.128 (77/600, NorthernSweden)
G=0.148 (32/216, Qatari)
G=0.079 (17/216, Vietnamese)
T=0.432 (64/148, SGDP_PRJ)
G=0.17 (12/70, Ancient Sardinia)
G=0.23 (9/40, GENOME_DK)
T=0.50 (6/12, Siberian)
G=0.50 (6/12, Siberian)

Clinical Significance: Reported in ClinVar
Gene : Consequence: None
Publications: 477 citations
Genomic View: See rs on genome

ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.

Release Version: 20231103111315

Population	Group	Sample Size	Ref Allele	Alt Allele	Ref HMOZ	Alt HMOZ	HTRZ	HWEP
Total	Global	357232	T=0.808816	G=0.191184	0.656442	0.03881	0.304749	21
European	Sub	303930	T=0.802514	G=0.197486	0.644721	0.039693	0.315586	2
African	Sub	12918	T=0.93149	G=0.06851	0.867781	0.0048	0.127419	0
African Others	Sub	468	T=0.959	G=0.041	0.931624	0.012821	0.055556	11
African American	Sub	12450	T=0.93044	G=0.06956	0.865382	0.004498	0.13012	0
Asian	Sub	6968	T=0.9470	G=0.0530	0.897245	0.003157	0.099598	0
East Asian	Sub	4998	T=0.9436	G=0.0564	0.890756	0.003601	0.105642	0
Other Asian	Sub	1970	T=0.9558	G=0.0442	0.913706	0.00203	0.084264	0
Latin American 1	Sub	1278	T=0.8028	G=0.1972	0.649452	0.043818	0.306729	0
Latin American 2	Sub	9326	T=0.6974	G=0.3026	0.487026	0.092215	0.420759	0
South Asian	Sub	5236	T=0.8373	G=0.1627	0.705882	0.031322	0.262796	2
Other	Sub	17576	T=0.82391	G=0.17609	0.684001	0.036186	0.279813	7

Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").

Download

Study	Population	Group	Sample Size	Ref Allele	Alt Allele
Allele Frequency Aggregator	Total	Global	357232	T=0.808816	G=0.191184
Allele Frequency Aggregator	European	Sub	303930	T=0.802514	G=0.197486
Allele Frequency Aggregator	Other	Sub	17576	T=0.82391	G=0.17609
Allele Frequency Aggregator	African	Sub	12918	T=0.93149	G=0.06851
Allele Frequency Aggregator	Latin American 2	Sub	9326	T=0.6974	G=0.3026
Allele Frequency Aggregator	Asian	Sub	6968	T=0.9470	G=0.0530
Allele Frequency Aggregator	South Asian	Sub	5236	T=0.8373	G=0.1627
Allele Frequency Aggregator	Latin American 1	Sub	1278	T=0.8028	G=0.1972
TopMed	Global	Study-wide	264690	T=0.835317	G=0.164683
gnomAD v4 - Genomes	Global	Study-wide	149192	T=0.844174	G=0.155826
gnomAD v4 - Genomes	European	Sub	78606	T=0.81416	G=0.18584
gnomAD v4 - Genomes	African	Sub	41544	T=0.93166	G=0.06834
gnomAD v4 - Genomes	American	Sub	15274	T=0.74178	G=0.25822
gnomAD v4 - Genomes	East Asian	Sub	5184	T=0.9346	G=0.0654
gnomAD v4 - Genomes	South Asian	Sub	4820	T=0.8469	G=0.1531
gnomAD v4 - Genomes	Ashkenazi Jewish	Sub	3470	T=0.7954	G=0.2046
gnomAD v4 - Genomes	Middle Eastern	sub	294	T=0.762	G=0.238
The PAGE Study	Global	Study-wide	78700	T=0.85094	G=0.14906
The PAGE Study	AfricanAmerican	Sub	32514	T=0.93095	G=0.06905
The PAGE Study	Mexican	Sub	10810	T=0.67956	G=0.32044
The PAGE Study	Asian	Sub	8318	T=0.9053	G=0.0947
The PAGE Study	PuertoRican	Sub	7918	T=0.7909	G=0.2091
The PAGE Study	NativeHawaiian	Sub	4534	T=0.9199	G=0.0801
The PAGE Study	Cuban	Sub	4230	T=0.7816	G=0.2184
The PAGE Study	Dominican	Sub	3828	T=0.8365	G=0.1635
The PAGE Study	CentralAmerican	Sub	2450	T=0.7110	G=0.2890
The PAGE Study	SouthAmerican	Sub	1982	T=0.6978	G=0.3022
The PAGE Study	NativeAmerican	Sub	1260	T=0.8111	G=0.1889
The PAGE Study	SouthAsian	Sub	856	T=0.860	G=0.140
38KJPN	JAPANESE	Study-wide	77444	T=0.90079	G=0.09921
Korean Genome Project 4K	KOREAN	Study-wide	7234	T=0.9406	G=0.0594
1000Genomes_30X	Global	Study-wide	6404	T=0.8648	G=0.1352
1000Genomes_30X	African	Sub	1786	T=0.9597	G=0.0403
1000Genomes_30X	Europe	Sub	1266	T=0.8310	G=0.1690
1000Genomes_30X	South Asian	Sub	1202	T=0.8220	G=0.1780
1000Genomes_30X	East Asian	Sub	1170	T=0.9291	G=0.0709
1000Genomes_30X	American	Sub	980	T=0.711	G=0.289
1000Genomes	Global	Study-wide	5008	T=0.8688	G=0.1312
1000Genomes	African	Sub	1322	T=0.9576	G=0.0424
1000Genomes	East Asian	Sub	1008	T=0.9236	G=0.0764
1000Genomes	Europe	Sub	1006	T=0.8320	G=0.1680
1000Genomes	South Asian	Sub	978	T=0.833	G=0.167
1000Genomes	American	Sub	694	T=0.723	G=0.277
Genetic variation in the Estonian population	Estonian	Study-wide	4480	T=0.7946	G=0.2054
The Avon Longitudinal Study of Parents and Children	PARENT AND CHILD COHORT	Study-wide	3854	T=0.8057	G=0.1943
UK 10K study - Twins	TWIN COHORT	Study-wide	3708	T=0.7991	G=0.2009
KOREAN population from KRGDB	KOREAN	Study-wide	2930	T=0.9481	G=0.0519
HGDP-CEPH-db Supplement 1	Global	Study-wide	2084	T=0.8335	G=0.1665
HGDP-CEPH-db Supplement 1	Est_Asia	Sub	470	T=0.945	G=0.055
HGDP-CEPH-db Supplement 1	Central_South_Asia	Sub	414	T=0.836	G=0.164
HGDP-CEPH-db Supplement 1	Middle_Est	Sub	350	T=0.809	G=0.191
HGDP-CEPH-db Supplement 1	Europe	Sub	320	T=0.775	G=0.225
HGDP-CEPH-db Supplement 1	Africa	Sub	242	T=0.930	G=0.070
HGDP-CEPH-db Supplement 1	America	Sub	216	T=0.569	G=0.431
HGDP-CEPH-db Supplement 1	Oceania	Sub	72	T=0.94	G=0.06
HapMap	Global	Study-wide	1890	T=0.8804	G=0.1196
HapMap	American	Sub	770	T=0.845	G=0.155
HapMap	African	Sub	690	T=0.930	G=0.070
HapMap	Asian	Sub	254	T=0.906	G=0.094
HapMap	Europe	Sub	176	T=0.801	G=0.199
Genome of the Netherlands Release 5	Genome of the Netherlands	Study-wide	998	T=0.802	G=0.198
Chileans	Chilean	Study-wide	626	T=0.725	G=0.275
Northern Sweden	ACPOP	Study-wide	600	T=0.872	G=0.128
Qatari	Global	Study-wide	216	T=0.852	G=0.148
A Vietnamese Genetic Variation Database	Global	Study-wide	216	T=0.921	G=0.079
SGDP_PRJ	Global	Study-wide	148	T=0.432	G=0.568
Ancient Sardinia genome-wide 1240k capture data generation and analysis	Global	Study-wide	70	T=0.83	G=0.17
The Danish reference pan genome	Danish	Study-wide	40	T=0.78	G=0.23
Siberian	Global	Study-wide	12	T=0.50	G=0.50

Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.

Genomic Placements

Sequence name	Change
GRCh38.p14 chr 19	NC_000019.10:g.39252525T>G
GRCh37.p13 chr 19	NC_000019.9:g.39743165T>G
IFNL4 RefSeqGene	NG_055295.1:g.1332A>C
GRCh38.p14 chr 19 fix patch HG2569_PATCH	NW_025791808.1:g.32907T>G

Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.

Allele: G (allele ID: 227802 )

ClinVar Accession	Disease Names	Clinical Significance
RCV000211192.4	interferons, peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin response - Efficacy	Drug-Response
RCV000211316.5	peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, and telaprevir response - Efficacy	Drug-Response
RCV000835188.1	not provided	Benign

Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".

Placement	T=	G
GRCh38.p14 chr 19	NC_000019.10:g.39252525=	NC_000019.10:g.39252525T>G
GRCh37.p13 chr 19	NC_000019.9:g.39743165=	NC_000019.9:g.39743165T>G
IFNL4 RefSeqGene	NG_055295.1:g.1332=	NG_055295.1:g.1332A>C
GRCh38.p14 chr 19 fix patch HG2569_PATCH	NW_025791808.1:g.32907=	NW_025791808.1:g.32907T>G

Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.

155 SubSNP, 25 Frequency, 3 ClinVar submissions

No	Submitter	Submission ID	Date (Build)
1	WI_SSAHASNP	ss12449652	Jul 11, 2003 (116)
2	ABI	ss44192664	Mar 14, 2006 (126)
3	ILLUMINA	ss66661174	Nov 30, 2006 (127)
4	ILLUMINA	ss67871944	Nov 30, 2006 (127)
5	ILLUMINA	ss68016642	Nov 30, 2006 (127)
6	ILLUMINA	ss70970599	May 26, 2008 (130)
7	ILLUMINA	ss71581269	May 17, 2007 (127)
8	ILLUMINA	ss75518341	Dec 07, 2007 (129)
9	AFFY	ss76465447	Dec 07, 2007 (129)
10	ILLUMINA	ss79281525	Dec 15, 2007 (130)
11	KRIBB_YJKIM	ss84786739	Dec 15, 2007 (130)
12	HUMANGENOME_JCVI	ss96306179	Feb 06, 2009 (130)
13	1000GENOMES	ss111372558	Jan 25, 2009 (130)
14	ILLUMINA	ss122903099	Dec 01, 2009 (131)
15	ENSEMBL	ss136265838	Dec 01, 2009 (131)
16	ILLUMINA	ss154469241	Dec 01, 2009 (131)
17	ILLUMINA	ss159643761	Dec 01, 2009 (131)
18	ILLUMINA	ss160949984	Dec 01, 2009 (131)
19	ILLUMINA	ss172398663	Jul 04, 2010 (132)
20	ILLUMINA	ss174719076	Jul 04, 2010 (132)
21	BCM-HGSC-SUB	ss208411054	Jul 04, 2010 (132)
22	1000GENOMES	ss228138282	Jul 14, 2010 (132)
23	1000GENOMES	ss237676136	Jul 15, 2010 (132)
24	1000GENOMES	ss243882613	Jul 15, 2010 (132)
25	GMI	ss283208450	May 04, 2012 (137)
26	PJP	ss292249558	May 09, 2011 (134)
27	ILLUMINA	ss481784914	May 04, 2012 (137)
28	ILLUMINA	ss481817209	May 04, 2012 (137)
29	ILLUMINA	ss482778596	Sep 08, 2015 (146)
30	ILLUMINA	ss485687146	May 04, 2012 (137)
31	EXOME_CHIP	ss491546753	May 04, 2012 (137)
32	ILLUMINA	ss537555932	Sep 08, 2015 (146)
33	TISHKOFF	ss565980841	Apr 25, 2013 (138)
34	SSMP	ss661845373	Apr 25, 2013 (138)
35	ILLUMINA	ss779050861	Sep 08, 2015 (146)
36	ILLUMINA	ss780687039	Sep 08, 2015 (146)
37	ILLUMINA	ss783289159	Sep 08, 2015 (146)
38	ILLUMINA	ss783360582	Sep 08, 2015 (146)
39	ILLUMINA	ss784241887	Sep 08, 2015 (146)
40	ILLUMINA	ss825612043	Apr 01, 2015 (144)
41	ILLUMINA	ss832550385	Sep 08, 2015 (146)
42	ILLUMINA	ss833154601	Jul 13, 2019 (153)
43	ILLUMINA	ss834513823	Sep 08, 2015 (146)
44	EVA-GONL	ss994296060	Aug 21, 2014 (142)
45	JMKIDD_LAB	ss1081901695	Aug 21, 2014 (142)
46	1000GENOMES	ss1363150534	Aug 21, 2014 (142)
47	DDI	ss1428402837	Apr 01, 2015 (144)
48	EVA_GENOME_DK	ss1578638595	Apr 01, 2015 (144)
49	EVA_UK10K_ALSPAC	ss1637962007	Apr 01, 2015 (144)
50	EVA_UK10K_TWINSUK	ss1680956040	Apr 01, 2015 (144)
51	EVA_DECODE	ss1698349591	Apr 01, 2015 (144)
52	EVA_SVP	ss1713662431	Apr 01, 2015 (144)
53	ILLUMINA	ss1752284786	Sep 08, 2015 (146)
54	ILLUMINA	ss1752284787	Sep 08, 2015 (146)
55	ILLUMINA	ss1917937286	Feb 12, 2016 (147)
56	WEILL_CORNELL_DGM	ss1937789906	Feb 12, 2016 (147)
57	ILLUMINA	ss1946535273	Feb 12, 2016 (147)
58	ILLUMINA	ss1946535274	Feb 12, 2016 (147)
59	ILLUMINA	ss1959863222	Feb 12, 2016 (147)
60	ILLUMINA	ss1959863223	Feb 12, 2016 (147)
61	AMU	ss1966653269	Feb 12, 2016 (147)
62	GENOMED	ss1968643486	Jul 19, 2016 (147)
63	JJLAB	ss2029674052	Sep 14, 2016 (149)
64	ILLUMINA	ss2094804032	Dec 20, 2016 (150)
65	ILLUMINA	ss2095084990	Dec 20, 2016 (150)
66	USC_VALOUEV	ss2158214129	Dec 20, 2016 (150)
67	HUMAN_LONGEVITY	ss2225739600	Dec 20, 2016 (150)
68	ILLUMINA	ss2633539540	Nov 08, 2017 (151)
69	GRF	ss2702824685	Nov 08, 2017 (151)
70	ILLUMINA	ss2710882570	Nov 08, 2017 (151)
71	GNOMAD	ss2962824520	Nov 08, 2017 (151)
72	AFFY	ss2985141452	Nov 08, 2017 (151)
73	AFFY	ss2985771910	Nov 08, 2017 (151)
74	SWEGEN	ss3017465748	Nov 08, 2017 (151)
75	ILLUMINA	ss3021904983	Nov 08, 2017 (151)
76	ILLUMINA	ss3021904984	Nov 08, 2017 (151)
77	BIOINF_KMB_FNS_UNIBA	ss3028669080	Nov 08, 2017 (151)
78	CSHL	ss3352301451	Nov 08, 2017 (151)
79	ILLUMINA	ss3625741613	Oct 12, 2018 (152)
80	ILLUMINA	ss3627931544	Oct 12, 2018 (152)
81	ILLUMINA	ss3627931545	Oct 12, 2018 (152)
82	ILLUMINA	ss3631511038	Oct 12, 2018 (152)
83	ILLUMINA	ss3633180182	Oct 12, 2018 (152)
84	ILLUMINA	ss3633890580	Oct 12, 2018 (152)
85	ILLUMINA	ss3634735056	Oct 12, 2018 (152)
86	ILLUMINA	ss3634735057	Oct 12, 2018 (152)
87	ILLUMINA	ss3635577385	Oct 12, 2018 (152)
88	ILLUMINA	ss3636422601	Oct 12, 2018 (152)
89	ILLUMINA	ss3637329123	Oct 12, 2018 (152)
90	ILLUMINA	ss3638226968	Oct 12, 2018 (152)
91	ILLUMINA	ss3639119746	Oct 12, 2018 (152)
92	ILLUMINA	ss3639570456	Oct 12, 2018 (152)
93	ILLUMINA	ss3640442364	Oct 12, 2018 (152)
94	ILLUMINA	ss3640442365	Oct 12, 2018 (152)
95	ILLUMINA	ss3643199923	Oct 12, 2018 (152)
96	ILLUMINA	ss3644723819	Oct 12, 2018 (152)
97	ILLUMINA	ss3644723820	Oct 12, 2018 (152)
98	URBANLAB	ss3650917431	Oct 12, 2018 (152)
99	ILLUMINA	ss3652330916	Oct 12, 2018 (152)
100	ILLUMINA	ss3652330917	Oct 12, 2018 (152)
101	ILLUMINA	ss3653913974	Oct 12, 2018 (152)
102	EGCUT_WGS	ss3684234271	Jul 13, 2019 (153)
103	EVA_DECODE	ss3702761755	Jul 13, 2019 (153)
104	ILLUMINA	ss3725728311	Jul 13, 2019 (153)
105	ACPOP	ss3743036020	Jul 13, 2019 (153)
106	ILLUMINA	ss3744166659	Jul 13, 2019 (153)
107	ILLUMINA	ss3744464425	Jul 13, 2019 (153)
108	ILLUMINA	ss3745035075	Jul 13, 2019 (153)
109	ILLUMINA	ss3745035076	Jul 13, 2019 (153)
110	EVA	ss3756060639	Jul 13, 2019 (153)
111	PAGE_CC	ss3772013098	Jul 13, 2019 (153)
112	ILLUMINA	ss3772532212	Jul 13, 2019 (153)
113	ILLUMINA	ss3772532213	Jul 13, 2019 (153)
114	KHV_HUMAN_GENOMES	ss3821308699	Jul 13, 2019 (153)
115	EVA	ss3835460735	Apr 27, 2020 (154)
116	HGDP	ss3847599454	Apr 27, 2020 (154)
117	SGDP_PRJ	ss3888209110	Apr 27, 2020 (154)
118	KRGDB	ss3938319898	Apr 27, 2020 (154)
119	EVA	ss3984742011	Apr 27, 2021 (155)
120	EVA	ss3984742012	Apr 27, 2021 (155)
121	EVA	ss3985854553	Apr 27, 2021 (155)
122	EVA	ss4017824567	Apr 27, 2021 (155)
123	TOMMO_GENOMICS	ss6183451232	Nov 02, 2024 (157)
124	EVA	ss6278257847	Nov 02, 2024 (157)
125	EVA	ss6319605278	Nov 02, 2024 (157)
126	EVA	ss6322043574	Nov 02, 2024 (157)
127	EVA	ss6322635155	Nov 02, 2024 (157)
128	EVA	ss6328306897	Nov 02, 2024 (157)
129	EVA	ss6333509980	Nov 02, 2024 (157)
130	YEGNASUBRAMANIAN_LAB	ss6347948477	Nov 02, 2024 (157)
131	EVA	ss6349963060	Nov 02, 2024 (157)
132	KOGIC	ss6398624638	Nov 02, 2024 (157)
133	TOPMED	ss8074712672	Nov 02, 2024 (157)
134	TOMMO_GENOMICS	ss8227741587	Nov 02, 2024 (157)
135	EVA	ss8237597025	Nov 02, 2024 (157)
136	1000G_HIGH_COVERAGE	ss8307234964	Nov 02, 2024 (157)
137	EVA	ss8315974642	Nov 02, 2024 (157)
138	EVA	ss8434820521	Nov 02, 2024 (157)
139	HUGCELL_USP	ss8499762604	Nov 02, 2024 (157)
140	EVA	ss8512102496	Nov 02, 2024 (157)
141	1000G_HIGH_COVERAGE	ss8612959685	Nov 02, 2024 (157)
142	SANFORD_IMAGENETICS	ss8624428706	Nov 02, 2024 (157)
143	SANFORD_IMAGENETICS	ss8662384922	Nov 02, 2024 (157)
144	TOMMO_GENOMICS	ss8786369190	Nov 02, 2024 (157)
145	EVA	ss8799404783	Nov 02, 2024 (157)
146	EVA	ss8800008723	Nov 02, 2024 (157)
147	YY_MCH	ss8817598807	Nov 02, 2024 (157)
148	EVA	ss8840544645	Nov 02, 2024 (157)
149	EVA	ss8852289083	Nov 02, 2024 (157)
150	EVA	ss8928090575	Nov 02, 2024 (157)
151	EVA	ss8953799633	Nov 02, 2024 (157)
152	EVA	ss8979546203	Nov 02, 2024 (157)
153	EVA	ss8981841489	Nov 02, 2024 (157)
154	EVA	ss8982309362	Nov 02, 2024 (157)
155	GNOMAD	ss10051201521	Nov 02, 2024 (157)
156	1000Genomes	NC_000019.9 - 39743165	Oct 12, 2018 (152)
157	1000Genomes_30X	NC_000019.10 - 39252525	Nov 02, 2024 (157)
158	The Avon Longitudinal Study of Parents and Children	NC_000019.9 - 39743165	Oct 12, 2018 (152)
159	Chileans	NC_000019.9 - 39743165	Apr 27, 2020 (154)
160	Genetic variation in the Estonian population	NC_000019.9 - 39743165	Oct 12, 2018 (152)
161	The Danish reference pan genome	NC_000019.9 - 39743165	Apr 27, 2020 (154)
162	gnomAD v4 - Genomes	NC_000019.10 - 39252525	Nov 02, 2024 (157)
163	Genome of the Netherlands Release 5	NC_000019.9 - 39743165	Apr 27, 2020 (154)
164	HGDP-CEPH-db Supplement 1	NC_000019.8 - 44435005	Apr 27, 2020 (154)
165	HapMap	NC_000019.10 - 39252525	Apr 27, 2020 (154)
166	KOREAN population from KRGDB	NC_000019.9 - 39743165	Apr 27, 2020 (154)
167	Korean Genome Project 4K	NC_000019.10 - 39252525	Nov 02, 2024 (157)
168	Northern Sweden	NC_000019.9 - 39743165	Jul 13, 2019 (153)
169	The PAGE Study	NC_000019.10 - 39252525	Jul 13, 2019 (153)
170	Ancient Sardinia genome-wide 1240k capture data generation and analysis	NC_000019.9 - 39743165	Apr 27, 2021 (155)
171	CNV burdens in cranial meningiomas Submission ignored due to conflicting rows: Row 291566 (NC_000019.9:39743164:T:G 42/790) Row 291567 (NC_000019.9:39743164:T:G 42/788)	-	Apr 27, 2021 (155)
172	CNV burdens in cranial meningiomas Submission ignored due to conflicting rows: Row 291566 (NC_000019.9:39743164:T:G 42/790) Row 291567 (NC_000019.9:39743164:T:G 42/788)	-	Apr 27, 2021 (155)
173	Qatari	NC_000019.9 - 39743165	Apr 27, 2020 (154)
174	SGDP_PRJ	NC_000019.9 - 39743165	Apr 27, 2020 (154)
175	Siberian	NC_000019.9 - 39743165	Apr 27, 2020 (154)
176	38KJPN	NC_000019.10 - 39252525	Nov 02, 2024 (157)
177	TopMed	NC_000019.10 - 39252525	Apr 27, 2021 (155)
178	UK 10K study - Twins	NC_000019.9 - 39743165	Oct 12, 2018 (152)
179	A Vietnamese Genetic Variation Database	NC_000019.9 - 39743165	Jul 13, 2019 (153)
180	ALFA	NC_000019.10 - 39252525	Nov 02, 2024 (157)
181	ClinVar	RCV000211192.4	Nov 02, 2024 (157)
182	ClinVar	RCV000211316.5	Nov 02, 2024 (157)
183	ClinVar	RCV000835188.1	Apr 27, 2020 (154)

History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).

Associated ID	History Updated (Build)
rs60715659	May 26, 2008 (130)

Added to this RefSNP Cluster:

Submission IDs	Observation SPDI	Canonical SPDI	Source RSIDs
277346, ss111372558, ss208411054, ss283208450, ss292249558, ss481784914, ss825612043, ss1698349591, ss1713662431, ss3639119746, ss3639570456, ss3643199923, ss3847599454	NC_000019.8:44435004:T:G	NC_000019.10:39252524:T:G	(self)
76557401, 42403218, 205386, 29972519, 4821118, 18889848, 45497292, 16320885, 1080480, 19831828, 40226090, 10730483, 42403218, 9366677, ss228138282, ss237676136, ss243882613, ss481817209, ss482778596, ss485687146, ss491546753, ss537555932, ss565980841, ss661845373, ss779050861, ss780687039, ss783289159, ss783360582, ss784241887, ss832550385, ss833154601, ss834513823, ss994296060, ss1081901695, ss1363150534, ss1428402837, ss1578638595, ss1637962007, ss1680956040, ss1752284786, ss1752284787, ss1917937286, ss1937789906, ss1946535273, ss1946535274, ss1959863222, ss1959863223, ss1966653269, ss1968643486, ss2029674052, ss2094804032, ss2095084990, ss2158214129, ss2633539540, ss2702824685, ss2710882570, ss2962824520, ss2985141452, ss2985771910, ss3017465748, ss3021904983, ss3021904984, ss3352301451, ss3625741613, ss3627931544, ss3627931545, ss3631511038, ss3633180182, ss3633890580, ss3634735056, ss3634735057, ss3635577385, ss3636422601, ss3637329123, ss3638226968, ss3640442364, ss3640442365, ss3644723819, ss3644723820, ss3652330916, ss3652330917, ss3653913974, ss3684234271, ss3743036020, ss3744166659, ss3744464425, ss3745035075, ss3745035076, ss3756060639, ss3772532212, ss3772532213, ss3835460735, ss3888209110, ss3938319898, ss3984742011, ss3984742012, ss3985854553, ss4017824567, ss6278257847, ss6319605278, ss6322635155, ss6328306897, ss6333509980, ss6347948477, ss6349963060, ss8227741587, ss8237597025, ss8315974642, ss8434820521, ss8512102496, ss8624428706, ss8662384922, ss8799404783, ss8800008723, ss8840544645, ss8953799633, ss8979546203, ss8981841489, ss8982309362	NC_000019.9:39743164:T:G	NC_000019.10:39252524:T:G	(self)
RCV000211192.4, RCV000211316.5, RCV000835188.1, 100485620, 578821067, 1695573, 48476536, 1234567, 200827052, 290258336, 12586055043, ss2225739600, ss3028669080, ss3650917431, ss3702761755, ss3725728311, ss3772013098, ss3821308699, ss6183451232, ss6322043574, ss6398624638, ss8074712672, ss8307234964, ss8499762604, ss8612959685, ss8786369190, ss8817598807, ss8852289083, ss8928090575, ss10051201521	NC_000019.10:39252524:T:G	NC_000019.10:39252524:T:G	(self)
ss12449652	NT_011109.15:12011382:T:G	NC_000019.10:39252524:T:G	(self)
ss44192664, ss66661174, ss67871944, ss68016642, ss70970599, ss71581269, ss75518341, ss76465447, ss79281525, ss84786739, ss96306179, ss122903099, ss136265838, ss154469241, ss159643761, ss160949984, ss172398663, ss174719076	NT_011109.16:12011382:T:G	NC_000019.10:39252524:T:G	(self)

Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.

477 citations for rs8099917

PMID	Title	Author	Year	Journal
19749757	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.	Tanaka Y et al.	2009	Nature genetics
19749758	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.	Suppiah V et al.	2009	Nature genetics
20060832	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.	Rauch A et al.	2010	Gastroenterology
20184973	Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.	Thio CL et al.	2010	Gastroenterology
20434452	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.	Honda M et al.	2010	Gastroenterology
20576307	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.	Abe H et al.	2010	Journal of hepatology
20648473	Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.	Akuta N et al.	2010	Hepatology (Baltimore, Md.)
20708617	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.	Fukuhara T et al.	2010	Gastroenterology
20728570	Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.	Stättermayer AF et al.	2011	Clinical gastroenterology and hepatology
20729732	Host genetic basis for hepatitis C virus clearance: a role for blood collection centers.	Selvarajah S et al.	2010	Current opinion in hematology
20803561	Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.	Grebely J et al.	2010	Hepatology (Baltimore, Md.)
20931559	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.	Urban TJ et al.	2010	Hepatology (Baltimore, Md.)
20950615	IL28B and the control of hepatitis C virus infection.	Balagopal A et al.	2010	Gastroenterology
21048934	IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.	Aparicio E et al.	2010	PloS one
21068134	HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.	Hayes CN et al.	2011	Gut
21080244	The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.	Pearlman BL et al.	2011	Current gastroenterology reports
21112657	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.	Sarrazin C et al.	2011	Journal of hepatology
21112660	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.	Kawaoka T et al.	2011	Journal of hepatology
21145800	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.	Abe H et al.	2011	Journal of hepatology
21145807	Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.	Scherzer TM et al.	2011	Journal of hepatology
21147189	IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.	Zhang L et al.	2011	Journal of hepatology
21228123	IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.	Ochi H et al.	2011	The Journal of general virology
21246582	Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.	Suzuki F et al.	2011	Hepatology (Baltimore, Md.)
21254157	Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.	Yu ML et al.	2011	Hepatology (Baltimore, Md.)
21274371	Peginterferon and ribavirin treatment for hepatitis C virus infection.	Tsubota A et al.	2011	World journal of gastroenterology
21303914	Interferon lambdas: the next cytokine storm.	Kelly C et al.	2011	Gut
21321200	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.	Hsu CS et al.	2011	Proceedings of the National Academy of Sciences of the United States of America
21325786	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.	Akuta N et al.	2012	Intervirology
21345258	Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.	Tavis JE et al.	2011	Genome medicine
21346780	IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.	Chen JY et al.	2011	Genes and immunity
21354446	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.	Bochud PY et al.	2011	Journal of hepatology
21360545	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	Sakamoto N et al.	2011	Journal of medical virology
21360716	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.	di Iulio J et al.	2011	Hepatology (Baltimore, Md.)
21374656	IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.	Moghaddam A et al.	2011	Hepatology (Baltimore, Md.)
21382156	Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.	Romero-Gomez M et al.	2011	Liver international
21384511	Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.	Eurich D et al.	2011	Liver transplantation
21389156	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.	Ito K et al.	2011	Journal of clinical microbiology
21390311	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.	Lagging M et al.	2011	PloS one
21466653	Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.	Coto-Llerena M et al.	2011	American journal of transplantation
21479134	IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.	Lin CY et al.	2011	PloS one
21501223	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.	Sinn DH et al.	2011	Journal of gastroenterology and hepatology
21503910	Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.	Hashimoto Y et al.	2011	Journal of medical virology
21567424	Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.	Toyoda H et al.	2011	Journal of medical virology
21613433	Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.	Fonseca-Coronado S et al.	2011	Journal of clinical microbiology
21628662	IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.	Chayama K et al.	2011	The Journal of infectious diseases
21692944	IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.	Lindh M et al.	2011	Journal of viral hepatitis
21694902	New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.	Quer J et al.	2010	Infection and drug resistance
21703176	Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.	Huang CF et al.	2012	Journal of hepatology
21703198	Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.	Tillmann HL et al.	2011	Journal of hepatology
21704279	Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.	Melis R et al.	2011	The Journal of molecular diagnostics
21721028	Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.	Marabita F et al.	2011	Hepatology (Baltimore, Md.)
21722179	Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.	Ladero JM et al.	2012	Journal of gastroenterology and hepatology
21739446	Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.	Toyoda H et al.	2011	Journal of medical virology
21745312	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.	Hayashi K et al.	2011	Liver international
21820962	Interferon-lambda and therapy for chronic hepatitis C virus infection.	Donnelly RP et al.	2011	Trends in immunology
21879313	Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.	Aizawa Y et al.	2012	Molecular and cellular biochemistry
21884576	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort.	Smith KR et al.	2011	Genome medicine
21889215	IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis.	Malhotra S et al.	2011	Journal of neuroimmunology
21898478	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.	Asahina Y et al.	2012	Hepatology (Baltimore, Md.)
21900787	A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.	Halfon P et al.	2011	European journal of gastroenterology & hepatology
21907615	Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.	Lyoo K et al.	2011	Journal of clinical virology
21911885	Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.	Ridruejo E et al.	2011	Annals of hepatology
21914076	IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.	Kawaoka T et al.	2011	Journal of viral hepatitis
21931540	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.	Suppiah V et al.	2011	PLoS medicine
21946415
21987611	IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.	Venegas M et al.	2011	World journal of gastroenterology
22003405	IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.	Dayyeh BK et al.	2011	PloS one
22013224	IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.	Shebl FM et al.	2011	The Journal of infectious diseases
22032680	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region.	Kawaoka T et al.	2011	Hepatology research
22046316	Genetic variation of the IL-28B promoter affecting gene expression.	Sugiyama M et al.	2011	PloS one
22052088	Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.	Osaki R et al.	2012	Molecular medicine reports
22087138	Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.	Li S et al.	2011	Hepatitis monthly
22095536	Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.	Toyoda H et al.	2012	Journal of medical virology
22098416	IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.	Cavalcante LN et al.	2012	Liver international
22098610	Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.	Ishizu Y et al.	2012	Journal of gastroenterology and hepatology
22110669	Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort.	van den Berg CH et al.	2011	PloS one
22118055	Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.	Lötsch J et al.	2011	Pharmacogenomics
22180014	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.	Bochud PY et al.	2012	Hepatology (Baltimore, Md.)
22180419	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.	Di Marco V et al.	2012	Haematologica
22192885	Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.	Beinhardt S et al.	2012	Gastroenterology
22193282	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.	Huang CF et al.	2012	Antiviral research
22209781	Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.	Wu X et al.	2012	Antiviral research
22214245	Genomics and proteomics in liver fibrosis and cirrhosis.	Hannivoort RA et al.	2012	Fibrogenesis & tissue repair
22234924	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.	Fischer J et al.	2012	Hepatology (Baltimore, Md.)
22239510	Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.	Miki D et al.	2012	Journal of viral hepatitis
22245236	Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.	Joshita S et al.	2012	Human immunology
22253715	Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3.	Rembeck K et al.	2012	PloS one
22253847	Sequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patients.	Reynolds JM et al.	2012	PloS one
22275900	Pharmacogenomics: what is next?	di Iulio J et al.	2011	Frontiers in pharmacology
22301466	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.	Liu CH et al.	2012	Antiviral therapy
22310928	Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma.	Ren S et al.	2012	Cancer immunology, immunotherapy
22314430	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.	Petta S et al.	2012	Journal of hepatology
22325058	Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population.	Li Y et al.	2012	International journal of immunogenetics
22328925	Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.	de Castellarnau M et al.	2012	PloS one
22329371	IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection.	Rao HY et al.	2012	Journal of viral hepatitis
22345656	IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.	Antaki N et al.	2012	Gut
22350701	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.	Ohnishi M et al.	2012	Journal of gastroenterology
22356575	The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.	Huang JF et al.	2012	Liver international
22368681	The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.	Sporea I et al.	2011	Hepatitis monthly
22374338	Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis.	Scagnolari C et al.	2012	Virus research
22382633	Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.	Miyase S et al.	2012	Journal of gastroenterology
22387386	Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.	Li W et al.	2012	Antiviral research
22404723	Lymphotropic hepatitis C virus has an interferon-resistant phenotype.	Inokuchi M et al.	2012	Journal of viral hepatitis
22432893	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.	Kawaoka T et al.	2012	Journal of gastroenterology and hepatology
22438096	Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.	Kobayashi M et al.	2012	Journal of gastroenterology
22441534	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.	Kim SR et al.	2012	Journal of gastroenterology
22497812	Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.	Clark PJ et al.	2012	Journal of viral hepatitis
22505587	Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.	Petta S et al.	2012	Antiviral therapy
22521237	Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment.	Habalová V et al.	2012	Molecular and cellular probes
22536875	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.	Saito H et al.	2012	Hepatology research
22537149	Development of new IL28B genotyping method using Invader Plus assay.	Kani S et al.	2012	Microbiology and immunology
22558263	IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway.	Liu MQ et al.	2012	PloS one
22591106	Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.	Chen Y et al.	2012	Alimentary pharmacology & therapeutics
22612669	Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.	Arase Y et al.	2012	Hepatology research
22613000	Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.	Ogawa E et al.	2012	Journal of hepatology
22626609	Factors that predict response of patients with hepatitis C virus infection to boceprevir.	Poordad F et al.	2012	Gastroenterology
22649509	IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population.	Shi X et al.	2012	PloS one
22664181	A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome.	Moreira S et al.	2012	Journal of virological methods
22719902	Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus.	Pedergnana V et al.	2012	PloS one
22742526	Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.	Schreiber J et al.	2012	Alimentary pharmacology & therapeutics
22754568	Glances in Immunology of HIV and HCV Infection.	Quaranta MG et al.	2012	Advances in virology
22806754	Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.	Akuta N et al.	2012	Hepatology (Baltimore, Md.)
22814458	Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping.	Poon KS et al.	2012	Journal of clinical microbiology
22842190	Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.	Shi KQ et al.	2012	Gene
22850127	The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C.	Simsek H et al.	2012	European journal of gastroenterology & hepatology
22863264	Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.	Miyashita M et al.	2012	Journal of viral hepatitis
22863269	Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.	Riva E et al.	2012	Journal of viral hepatitis
22889955	Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.	Furusyo N et al.	2012	Journal of hepatology
22898703	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.	Liu CH et al.	2012	Antiviral therapy
22904616	New developments in the management of hepatitis C virus infection: focus on boceprevir.	Berenguer M et al.	2012	Biologics
22913807	Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.	Maor Y et al.	2013	Haemophilia
22930507	Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.	Akuta N et al.	2012	Journal of medical virology
22934000	Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics.	Chua EW et al.	2012	Frontiers in pharmacology
22966241	The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.	Bellanti F et al.	2012	Clinical & developmental immunology
22992668	Pharmacogenomics knowledge for personalized medicine.	Whirl-Carrillo M et al.	2012	Clinical pharmacology and therapeutics
23020144	Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy.	Shaker OG et al.	2012	Journal of gastroenterology and hepatology
23049477	Association of IRGM polymorphisms and susceptibility to pulmonary tuberculosis in Zahedan, Southeast Iran.	Bahari G et al.	2012	TheScientificWorldJournal
23103287	IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.	Guzmán-Fulgencio M et al.	2013	The Journal of infection
23109451	IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.	Martínez-Gómez LE et al.	2012	Annals of hepatology
23133602	Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.	Vidal F et al.	2012	PloS one
23135173	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.	Fernández-Rodríguez A et al.	2013	AIDS (London, England)
23135762	Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.	Watanabe T et al.	2013	Gut
23142377	Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.	Luo Y et al.	2013	Gene
23145040	Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.	Rivero-Juárez A et al.	2012	PloS one
23145987	Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation.	Ikegami T et al.	2013	Hepatology research
23149444	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.	D'Avolio A et al.	2012	Therapeutic drug monitoring
23154876	Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.	Toyoda H et al.	2013	Journal of medical virology
23161429	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.	Kohjima M et al.	2013	Journal of medical virology
23171003	Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.	Lim YP et al.	2012	BMC gastroenterology
23173032	None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.	Jeng WJ et al.	2012	PloS one
23213063	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.	Yoshio S et al.	2013	Hepatology (Baltimore, Md.)
23216931	Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-α plus ribavirin in patients with chronic hepatitis C.	Noguchi Y et al.	2013	Hepatology research
23227209	Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese.	Chen J et al.	2012	PloS one
23231085	IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.	Antaki N et al.	2013	Journal of viral hepatitis
23246359	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.	Huang CF et al.	2013	Journal of clinical virology
23259930	Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.	Sanabani SS et al.	2012	BMC infectious diseases
23266640	Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.	Zheng MH et al.	2013	Gene
23268841	Pharmacogenomics of hepatitis C infections: personalizing therapy.	Booth DR et al.	2012	Genome medicine
23281610	Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C.	Shimoyama Y et al.	2013	Hepatology research
23284866	Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.	Yu ML et al.	2012	PloS one
23296193	IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.	Hsu CS et al.	2013	Antiviral therapy
23297176	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	Kurosaki M et al.	2013	Journal of medical virology
23314745	Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.	Domagalski K et al.	2013	European journal of clinical microbiology & infectious diseases
23333445	Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.	Biggins SW et al.	2013	Journal of hepatology
23356752	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.	Hayashi K et al.	2013	Hepatology research
23426277	Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C.	Hodo Y et al.	2013	Clinical cancer research
23442843	Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.	Jung YK et al.	2013	Journal of clinical gastroenterology
23449268	HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.	Seto WK et al.	2013	Clinical infectious diseases
23455512	IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test.	Gélinas JF et al.	2013	Immunogenetics
23486666	'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.	Bucci C et al.	2013	The Journal of general virology
23490371	Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients.	Angulo J et al.	2013	Journal of viral hepatitis
23490377	Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.	Piluso A et al.	2013	Journal of viral hepatitis
23490380	An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.	Takahashi H et al.	2013	Journal of viral hepatitis
23542346	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.	Furusyo N et al.	2013	Journal of hepatology
23560893	Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.	Huang CF et al.	2013	Journal of gastroenterology and hepatology
23565619	IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.	Jiménez-Sousa MA et al.	2013	Journal of viral hepatitis
23586360	Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.	Yu F et al.	2013	Scandinavian journal of gastroenterology
23591768	Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.	Murata K et al.	2014	Journal of gastroenterology
23611115	Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.	Yang M et al.	2013	Journal of gastroenterology and hepatology
23611467	CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation.	Paramel GV et al.	2013	Clinical science (London, England
23613588	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.	Su TH et al.	2013	Proceedings of the National Academy of Sciences of the United States of America
23650587	Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment.	Kawamura Y et al.	2012	FEBS open bio
23689988	Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.	Oze T et al.	2014	Journal of gastroenterology
23689989	IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.	Sato M et al.	2014	Journal of gastroenterology
23730840	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.	Seto WK et al.	2013	Journal of viral hepatitis
23777929	Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease.	Affandi JS et al.	2013	Human immunology
23784126	Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.	Akuta N et al.	2013	Journal of clinical microbiology
23829453	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.	Chen MY et al.	2014	Journal of gastroenterology and hepatology
23831131	The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C.	Lazarevic I et al.	2013	Journal of clinical virology
23861088	A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.	Hara T et al.	2013	Journal of medical virology
23866096	The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients.	Derbala M et al.	2013	Virology
23919217	Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.	Fujino T et al.	2013	World journal of gastrointestinal pharmacology and therapeutics
23978349	Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities.	Kanwal F et al.	2014	Clinical gastroenterology and hepatology
24039372	Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.	Sato K et al.	2013	World journal of gastroenterology
24096049	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients.	Yu ML et al.	2014	Journal of hepatology
24099469	Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.	Ogawa E et al.	2013	Alimentary pharmacology & therapeutics
24102823	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.	Ragheb MM et al.	2014	Liver international
24117654	Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.	Tsubota A et al.	2014	Journal of gastroenterology and hepatology
24118788	Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients.	Al-Qahtani AA et al.	2014	Liver international
24144988	Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population.	Jin G et al.	2014	Infection, genetics and evolution
24166425	α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.	Shimada N et al.	2014	Journal of medical virology
24192751	Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Kawakami Y et al.	2014	Antiviral therapy
24197875	Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.	Akuta N et al.	2014	Journal of clinical microbiology
24205831	Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.	Stättermayer AF et al.	2014	Alimentary pharmacology & therapeutics
24219707	Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.	Roberts SK et al.	2014	Journal of gastroenterology and hepatology
24308755	The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.	Covolo L et al.	2014	Alimentary pharmacology & therapeutics
24311440	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.	Honda M et al.	2014	Hepatology (Baltimore, Md.)
24316030	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.	Boglione L et al.	2014	Antiviral research
24325201	Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.	Huang CI et al.	2014	Journal of gastroenterology and hepatology
24355007	Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.	Nozawa Y et al.	2014	Tissue antigens
24362944	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.	Fujino H et al.	2014	Journal of gastroenterology
24382214	Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.	Kawaoka T et al.	2014	Hepatology research
24387833	No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance.	Visco-Comandini U et al.	2014	Digestive and liver disease
24438678	Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis.	Lee DH et al.	2014	Journal of viral hepatitis
24438680	IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients.	Jiménez-Sousa MA et al.	2014	Journal of viral hepatitis
24477330	A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.	Murata M et al.	2014	Journal of infection and chemotherapy
24517330	Can we include genetic variants with high linkage disequilibrium into a multiple logistic model? Author's reply.	Palmieri O et al.	2014	Liver international
24517415	Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.	Wu H et al.	2015	Liver international
24582569	Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.	Yilmaz E et al.	2014	Clinical gastroenterology and hepatology
24606109	A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.	Shimada N et al.	2014	Hepatology research
24620020	Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus.	Egli A et al.	2014	The Journal of infectious diseases
24637774	Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.	Sato M et al.	2014	PloS one
24642705	IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.	Liu T et al.	2014	PloS one
24646752	IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.	Ochi H et al.	2014	The Journal of general virology
24659876	Individualization of chronic hepatitis C treatment according to the host characteristics.	Gatselis NK et al.	2014	World journal of gastroenterology
24662995	IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan.	Khudayberganova D et al.	2014	PloS one
24692042	The interaction of a single-nucleotide polymorphism with age on response to interferon-α and ribavirin therapy in female patients with hepatitis C infection.	Nishino J et al.	2014	Journal of medical virology
24696021	Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment.	Juniastuti et al.	2014	Journal of clinical microbiology
24707127	Immunologic, metabolic and genetic factors in hepatitis C virus infection.	Fierro NA et al.	2014	World journal of gastroenterology
24716637	Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.	Yokoyama S et al.	2014	Journal of viral hepatitis
24726902	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms.	Boglione L et al.	2014	Antiviral research
24731162	Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.	Ogawa E et al.	2014	Journal of gastroenterology and hepatology
24750345	ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.	Matsuura K et al.	2014	Journal of viral hepatitis
24750545	Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.	Konishi H et al.	2014	Journal of viral hepatitis
24768758	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.	Eslam M et al.	2014	Journal of hepatology
24770613	Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.	Layden JE et al.	2014	Transplantation
24797623	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.	Akuta N et al.	2014	Journal of medical virology
24812506	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.	Liu CH et al.	2014	International journal of nanomedicine
24819603	Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C.	Tsubota A et al.	2014	PloS one
24840315	Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B.	Karataylı SC et al.	2015	Liver international
24897020	Genetic variants in human leukocyte antigen-DP influence both hepatitis C virus persistence and hepatitis C virus F protein generation in the Chinese Han population.	Xu X et al.	2014	International journal of molecular sciences
24910341	Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.	Masaki N et al.	2014	Journal of gastroenterology and hepatology
24914551	Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.	Firdaus R et al.	2014	PloS one
24924923	The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection.	Domagalski K et al.	2014	European journal of clinical microbiology & infectious diseases
24929144	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.	Umemura T et al.	2014	Human immunology
24944790	Screening for 392 polymorphisms in 141 pharmacogenes.	Kim JY et al.	2014	Biomedical reports
24962339	Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.	Shirasaki T et al.	2014	Hepatology (Baltimore, Md.)
24969847	Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.	Peng CY et al.	2014	BMC gastroenterology
24976707	Human genes involved in hepatitis B virus infection.	Zeng Z et al.	2014	World journal of gastroenterology
24995561	Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.	Hayashi K et al.	2015	Journal of gastroenterology and hepatology
25032178	KASL clinical practice guidelines: management of hepatitis C.		2014	Clinical and molecular hepatology
25032184	No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.	Heo NY et al.	2014	Clinical and molecular hepatology
25071317	Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children.	Indolfi G et al.	2014	World journal of gastroenterology
25100136	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan.	Oda K et al.	2014	Journal of medical virology
25115611	Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.	Shaker O et al.	2015	Cell biochemistry and biophysics
25130512	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.	Fernández-Carrillo C et al.	2014	Journal of clinical virology
25171028	Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.	Yee BE et al.	2014	European journal of gastroenterology & hepatology
25196718	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.	Kumada H et al.	2015	Hepatology research
25225180	Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis.	Zhang L et al.	2014	Human immunology
25278709	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.	Rosso C et al.	2014	World journal of gastroenterology
25279449	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.	Cusato J et al.	2015	Antiviral therapy
25312023	IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.	Dong ZX et al.	2015	Journal of digestive diseases
25393304	Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.	Susser S et al.	2014	PloS one
25429378	Noninvasive characterization of graft steatosis after liver transplantation.	Karlas T et al.	2015	Scandinavian journal of gastroenterology
25462177	Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.	Aziz H et al.	2015	International journal of infectious diseases
25564756	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy.	Itakura J et al.	2015	Hepatology research
25587543	T-cell cytokine gene polymorphisms and vitamin D pathway gene polymorphisms in end-stage renal disease due to type 2 diabetes mellitus nephropathy: comparisons with health status and other main causes of end-stage renal disease.	Grzegorzewska AE et al.	2014	Journal of diabetes research
25639146	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.	Wong GL et al.	2015	Journal of gastroenterology and hepatology
25652367	IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.	Shaikh N et al.	2015	Journal of medical virology
25660111	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.	Boglione L et al.	2015	Antiviral research
25664396	Gene polymorphisms of interleukin 28B and the risk to chronic hepatitis B virus infection in Thai.	Kimkong I et al.	2015	Tissue antigens
25666200	The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection.	Wang M et al.	2015	Archives of virology
25703417	Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population.	Imran M et al.	2015	APMIS
25769643	IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.	Zheng H et al.	2015	Clinics and research in hepatology and gastroenterology
25803108	Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.	Moqueet N et al.	2015	International journal of molecular sciences
25810555	Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.	Sato M et al.	2015	Journal of virology
25837166	IL28B is associated with outcomes of chronic HBV infection.	Shi X et al.	2015	Yonsei medical journal
25852275	Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.	Ishiguro H et al.	2015	World journal of gastroenterology
25863261	Comparison of four methods of genotyping IL28B polymorphisms in chronic hepatitis C patients.	Delvaux N et al.	2015	Journal of virological methods
25904097	The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay.	Kan T et al.	2016	Journal of gastroenterology
25907669	Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a.	Yamada K et al.	2015	Journal of medical virology
25910563	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection.	Huang CF et al.	2015	The Kaohsiung journal of medical sciences
25918016	Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.	Cariani E et al.	2016	The pharmacogenomics journal
25936570	Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4.	Rady NH et al.	2015	Cytokine
25962810	A meta-analysis of the association between IL28B polymorphisms and infection susceptibility of hepatitis B virus in Asian population.	Chen J et al.	2015	BMC gastroenterology
25970604	IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.	Olmedo DB et al.	2015	Journal of medical virology
26003758	Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.	Fathy MM et al.	2015	Cytokine
26060059	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.	Boglione L et al.	2015	Archives of virology
26075078	MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.	Asada A et al.	2015	Biomedical reports
26115415	The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.	Domagalski K et al.	2015	PloS one
26130141	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.	Liu CH et al.	2015	Scientific reports
26150150	Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.	Lamoury FM et al.	2015	The Journal of molecular diagnostics
26156685	Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.	Dzekova-Vidimliski P et al.	2015	Renal failure
26177560	Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.	Resham S et al.	2015	APMIS
26191484	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.	Calisti G et al.	2015	SpringerPlus
26252875	Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.	Kumada H et al.	2016	Journal of gastroenterology and hepatology
26263394	Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal.	Kinkel HT et al.	2015	PloS one
26269684	Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.	Haj-Sheykholeslami A et al.	2015	World journal of gastroenterology
26280154	Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.	Esmail MA et al.	2016	Journal of medical virology
26289410	Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin.	Atsukawa M et al.	2016	Hepatology research
26334898	Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.	Bellanti F et al.	2015	Medicine
26352693	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens.	Tamaki N et al.	2015	PloS one
26394672	Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-α, With Severity of Disease Caused by Andes Virus.	Angulo J et al.	2015	Clinical infectious diseases
26403160	Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.	Hayashi N et al.	2016	Journal of gastroenterology
26420957	Chronic hepatitis C virus infection and lipoprotein metabolism.	Aizawa Y et al.	2015	World journal of gastroenterology
26468348	Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city.	Mousavi Nasab SD et al.	2015	Gastroenterology and hepatology from bed to bench
26470765	Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.	Zhang R et al.	2016	Gut and liver
26485009	Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.	Sticchi L et al.	2015	The new microbiologica
26546777	IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy.	de Sá KS et al.	2016	Cytokine
26556986	Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.	Ramos-Lopez O et al.	2015	World journal of gastroenterology
26563120	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.	Sarin SK et al.	2016	Hepatology international
26602024	Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk.	Lee MH et al.	2015	Scientific reports
26660164	Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study.	Ikezaki H et al.	2016	Archives of virology
26670100	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.	About F et al.	2015	PloS one
26699619	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.	Wiegand SB et al.	2015	PloS one
26741362	Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico.	Gonzalez-Aldaco K et al.	2016	PloS one
26825765	Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013.	Suzuki M et al.	2016	Journal of pediatric gastroenterology and nutrition
26848682	Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections.	Assone T et al.	2016	Viruses
26893844	Association of the interleukin-18 receptor 1 and interleukin-18 receptor accessory protein polymorphisms with the risk of esophageal cancer.	Zhu J et al.	2016	Biomedical reports
26965318	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.	Lu MY et al.	2016	Scientific reports
26973228	Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.	de Seixas Santos Nastri AC et al.	2016	Archives of virology
26984148	Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.	Moqueet N et al.	2016	The Journal of infectious diseases
26986131	Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients.	Hsiao LT et al.	2016	Medicine
26991414	Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.	Tahata Y et al.	2016	Journal of medical virology
27035616	Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer.	Moreira JP et al.	2016	Virology
27047766	Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System.	Taniguchi M et al.	2016	Journal of clinical and translational hepatology
27047769	Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients.	Kumar A et al.	2016	Journal of clinical and translational hepatology
27135246	Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.	Ibrahim MK et al.	2016	PloS one
27139837	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia.	Cusato J et al.	2016	Pharmacogenetics and genomics
27155288	Seasonal influenza A/H3N2 virus infection and IL-1Β, IL-10, IL-17, and IL-28 polymorphisms in Iranian population.	Rogo LD et al.	2016	Journal of medical virology
27224844	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.	Sheridan DA et al.	2016	Liver international
27226800	The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection.	Heidari Z et al.	2016	Hepatitis monthly
27236152	Association of HLA-DQ and IFNL4 polymorphisms with susceptibility to hepatitis B virus infection and clearance.	Fan JH et al.	2016	Annals of hepatology
27275739	Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.	Chiu KW et al.	2016	PloS one
27313470	Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma.	Zhang Y et al.	2016	OncoTargets and therapy
27340680	Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection.	Waldron PR et al.	2016	Journal of immunology research
27346846	Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.	Fülöp B et al.	2016	Journal of viral hepatitis
27357737	Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.	Akuta N et al.	2017	Journal of medical virology
27461217	A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance.	Singh P et al.	2016	Molecular biology reports
27492404	Population Polymorphism of IFNL3 and IFNL4 Genes of Type 3 Interferon Associated with Spontaneous Clearance of Hepatitis C Virus in Representatives of Caucasian and Mongoloid Races.	Malov IV et al.	2016	Bulletin of experimental biology and medicine
27498543	Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?	Mansoor S et al.	2016	The Journal of general virology
27547017	Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.	Severson TJ et al.	2016	World journal of gastroenterology
27561198	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.	Hsu CS et al.	2016	Scientific reports
27563641	Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.	Gastroenterology CA et al.	2016	Canadian journal of gastroenterology & hepatology
27595449	Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients.	Grzegorzewska AE et al.	2016	Vaccine
27617784	Increased Serum Levels of IL-28 and IL-29 and the Protective Effect of IL28B rs8099917 Polymorphism in Patients with Hashimoto's Thyroiditis.	Arpaci D et al.	2016	Immunological investigations
27656234	The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis.	Lin Z et al.	2016	Hepatitis monthly
27660680	Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective.	Afzal MS et al.	2016	World journal of hepatology
27723809	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.	Matsunami K et al.	2016	PloS one
27733412	Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study.	Yan LB et al.	2016	BMJ open
27751759	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C.	Mah YH et al.	2016	Journal of the Formosan Medical Association = Taiwan yi zhi
27810495	Psoriasis risk SNPs and their association with HIV-1 control.	Nititham J et al.	2017	Human immunology
27812403	The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia.	Bogdanović Z et al.	2016	PeerJ
27895405	Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.	Domagalski K et al.	2016	World journal of gastroenterology
27917361	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.	Mangia A et al.	2016	SpringerPlus
27917597	Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.	Durier N et al.	2017	Journal of viral hepatitis
27943542	HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.	Xiong H et al.	2017	Journal of viral hepatitis
27998720	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment.	Huang CF et al.	2017	EBioMedicine
28036111	Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.	Murakawa M et al.	2017	Journal of medical virology
28058039	Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.	Palenzuela Gardón D et al.	2017	Journal of biomolecular techniques
28178648	Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.	Kuo SH et al.	2017	Oncotarget
28214926	Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.	Alborzi A et al.	2017	Medical microbiology and immunology
28224025	Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran.	Karkhane M et al.	2016	Gastroenterology and hepatology from bed to bench
28253210	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.	Uygun A et al.	2017	European journal of gastroenterology & hepatology
28261382	Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.	Yamagiwa S et al.	2017	World journal of hepatology
28315743	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.	Boglione L et al.	2017	Infection, genetics and evolution
28335783	SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.	Li Y et al.	2017	Virology journal
28419488	Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia.	Biswas A et al.	2017	Transfusion
28453396	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia.	Cusato J et al.	2017	Pharmacogenomics
28467457	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.	Moqueet N et al.	2017	PloS one
28502145	Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients.	Ea R et al.	2015	The Egyptian journal of immunology
28513591	Zinc is a potent and specific inhibitor of IFN-λ3 signalling.	Read SA et al.	2017	Nature communications
28525983	Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients - a prospective study.	Grzegorzewska AE et al.	2017	BMC nephrology
28560477	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.	Suda G et al.	2018	Journal of gastroenterology
28579527	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C.	Boglione L et al.	2017	Infection, genetics and evolution
28614389	Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.	Lee JW et al.	2017	PloS one
28638221	Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.	Świątek-Kościelna B et al.	2017	World journal of gastroenterology
28655358	The association between interleukin-28B gene polymorphisms as a potential biomarker and the risk of chronic Periodontitis in an Iranian population.	Heidari Z et al.	2017	Head & face medicine
28681817	The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.	Jalilian S et al.	2017	Indian journal of medical microbiology
28703131	EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.	Asnavandi M et al.	2017	Genes and immunity
28739427	The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.	Sakhaee F et al.	2017	Infection, genetics and evolution
28834572	Multiple genetic variants associated with posttransplantation diabetes mellitus in Chinese Han populations.	Chen J et al.	2018	Journal of clinical laboratory analysis
28874741	A functional IFN-λ4-generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma.	Chinnaswamy S et al.	2017	Scientific reports
28928439	Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.	Hai H et al.	2017	Scientific reports
28962822	High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.	Cheng CH et al.	2017	The Kaohsiung journal of medical sciences
29022122	Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection.	Nguyen LT et al.	2018	Archives of virology
29040985	Serum IFN-λ3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C.	Imoto S et al.	2017	Digestive diseases (Basel, Switzerland)
29055988	[Association of HLA-DQ and IFNL4 polymorphisms with hepatitis B virus infection and clearance].	Chen H et al.	2017	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
29062905	The impact of the recipient and donor interferon lambda-3 polymorphism on the course of HCV infection following liver transplantation.	Wieczorek-Godlewska R et al.	2017	Clinical and experimental hepatology
29095252	Association of interleukin-28B polymorphisms with platelet count and liver function recovery after liver transplant.	Li Y et al.	2017	Medicine
29104462	Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.	Nakamoto S et al.	2017	International journal of medical sciences
29129607	Polymorphisms in HLA-C and KIR alleles are not associated with HAM/TSP risk in HTLV-1-infected subjects.	Assone T et al.	2018	Virus research
29130827	Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population.	Vargas-Castillo AB et al.	2018	Viral immunology
29226133	Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients.	Grzegorzewska AE et al.	2017	BioMed research international
29264884	Distribution of polymorphisms rs12979860, rs8099917 and rs12980275 IL28B in patients with chronic hepatitis C.	Wysocka-Leszczyńska J et al.	2017	Advances in clinical and experimental medicine
29285382	IL18 rs360719 A>G, IL18R1 rs13015714 G>T, IL18RAP rs917997 C>T and IL28B rs8099917 T>G polymorphisms and risk of gastric cardiac adenocarcinoma.	Yin J et al.	2017	Molecular and clinical oncology
29302390	Association between genetic polymorphisms of the IL28B gene and leukomonocyte in Chinese hepatitis B virus-infected individuals.	Song Y et al.	2017	PeerJ
29340806	Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients.	Naeemi H et al.	2018	Archives of virology
29369421	Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.	Lindgren M et al.	2018	European journal of haematology
29404438	A global perspective on hepatitis B-related single nucleotide polymorphisms and evolution during human migration.	Tai DI et al.	2017	Hepatology communications
29405153	Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy.	Srinidhi BV et al.	2017	Indian journal of medical microbiology
29429413	A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.	Zia A et al.	2018	Infectious diseases of poverty
29499724	IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.	Echeverría N et al.	2018	Virology journal
29504692	Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen.	Ikeda H et al.	2018	Hepatology research
29517696	Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes.	Huang CI et al.	2018	Medicine
29562888	IFNΛ3/4 locus polymorphisms and IFNΛ3 circulating levels are associated with COPD severity and outcomes.	Egli A et al.	2018	BMC pulmonary medicine
29686997	Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis.	Chiu KW et al.	2018	BioMed research international
29739095	Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China.	Qiao K et al.	2018	Clinical laboratory
29755645	Hepatic steatosis in chronic hepatitis B: a study of metabolic and genetic factors.	Baclig MO et al.	2018	International journal of molecular epidemiology and genetics
29866105	Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women.	Xie Z et al.	2018	BMC infectious diseases
29888255	Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms.	de Souza SL et al.	2018	BioMed research international
29910570	The Role of Biochemical Variations and Genotype Testing in Determining the Virological Response of Patients Infected with Hepatitis C Virus.	Shoukat A et al.	2018	Journal of global infectious diseases
29935858	Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients.	Grzegorzewska AE et al.	2018	Vaccine
29963045	MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications.	Ellwanger JH et al.	2018	Frontiers in immunology
30016335	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.	Wei L et al.	2018	PloS one
30077763	IL28B, IL29 and micro-RNA 548 in subacute sclerosing panencephalitis as a rare disease.	Cakmak Genc G et al.	2018	Gene
30157968	Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese.	Chen JY et al.	2018	Arthritis research & therapy
30234607	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.	Bibert S et al.	2018	AIDS (London, England)
30344298	Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study.	Buivydiene A et al.	2018	Medicina (Kaunas, Lithuania)
30381417	Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.	Akuta N et al.	2019	Journal of clinical microbiology
30402710	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.	Zakaria ZA et al.	2019	Immunologic research
30431653	Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.	Khan AJ et al.	2019	Journal of medical virology
30623518	Association of serum interferon-λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents.	Inoue-Shinomiya E et al.	2019	Hepatology research
30695542	FREQUENCY OF OCCURRENCE OF POLYMORPHIC VARIANTS OF IL28B GENE AND GENOTYPES OF HEPATITIS C VIRUS IN POPULATION OF YAKUTIA: CLINICAL OUTCOMES.	Semenov SI et al.	2017	Zhurnal mikrobiologii, epidemiologii i immunobiologii
30775813	Occult hepatitis C virus infection in patients with beta-thalassemia major: Is it a neglected and unexplained phenomenon?	Ayadi A et al.	2019	Journal of cellular biochemistry
30821879	Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?	Ayadi A et al.	2019	Hepatology research
30988680	The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin.	Kalantari H et al.	2019	Journal of research in medical sciences
31019283	Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests.	Thauvin-Robinet C et al.	2019	European journal of human genetics
31060998	IL-28B genetic variation, gender, age, jaundice, hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus.	Fedorchenko SV et al.	2019	The Turkish journal of gastroenterology
31144350	IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment.	Morihara D et al.	2019	Journal of gastroenterology and hepatology
31196204	Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population.	Keshavarz M et al.	2019	Virology journal
31201901	The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis.	Zhao Z et al.	2019	Microbial pathogenesis
31227111
31396258	Host Genetics of Cytomegalovirus Pathogenesis.	Sezgin E et al.	2019	Frontiers in genetics
31475028	Host Genetic Determinants of Hepatitis B Virus Infection.	Zhang Z et al.	2019	Frontiers in genetics
31485460	Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?	Ferrari SM et al.	2019	Journal of immunology research
31488196	Host susceptibility to severe influenza A virus infection.	Clohisey S et al.	2019	Critical care (London, England)
31568008	The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis.	Qin S et al.	2019	Medicine
31642723	Single nucleotide polymorphisms rs12979860 and rs8099917 in IL-28B and spontaneous clearance of hepatitis C genotype 4.	Youssef AR et al.	2020	British journal of biomedical science
31645053	Correlation between female sex, IL28B genotype, and the clinical severity of bronchiolitis in pediatric patients.	Astudillo P et al.	2020	Pediatric research
31793339	PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression.	Youssef SS et al.	2022	Archives of physiology and biochemistry
31803800	IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population.	Roy N et al.	2019	Virusdisease
31838260	Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.	Nafari AH et al.	2020	Infection, genetics and evolution
31999635	Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients.	Khan MS et al.	2018	Journal of infection in developing countries
32053513	Elevated serum levels of adiponectin and interlukin-28B after IFN/RIB therapy in hepatitis C virus-infected patients.	Sadeghi K et al.	2019	Journal of infection in developing countries
32058988	IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury.	Jordovic J et al.	2019	Journal of infection in developing countries
32180251	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.	Terashima T et al.	2020	Journal of gastroenterology and hepatology
32357928	Association between IL28B Polymorphisms and Outcomes of Hepatitis B Virus Infection: A meta-analysis.	Zhao J et al.	2020	BMC medical genetics
32368983	Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients.	Elsheredy AG et al.	2020	Endocrine, metabolic & immune disorders drug targets
32449798	AIDS incidence and survival in a hospital-based cohort of HIV-positive patients from São Paulo, Brazil: The role of IFN-λ4 polymorphisms.	da Silva Prates G et al.	2021	Journal of medical virology
32459809	Unique insights from ClinicalTrials.gov by mining protein mutations and RSids in addition to applying the Human Phenotype Ontology.	Alag S et al.	2020	PloS one
32622719	Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.	El-Fattah MA et al.	2021	Clinics and research in hepatology and gastroenterology
32646311	Association Between IL28B, IL29 Gene Polymorphisms and Clinical Manifestations of Behçet's Disease.	Cakmak Genc G et al.	2021	Immunological investigations
32656614	Impact of IL28 Genotypes and Modeling the Interactions of HCV Core Protein on Treatment of Hepatitis C.	Hashempour T et al.	2020	Interdisciplinary sciences, computational life sciences
32749108	Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.	Shaheen M et al.	2020	Critical reviews in eukaryotic gene expression
32936528	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19).	Zubiaur P et al.	2020	Clinical and translational science
32957410	Association of cytokine gene polymorphisms with chronic hepatitis C virus genotype 1b infection in Chinese Han population: An observational study.	Jing JS et al.	2020	Medicine
33257634	Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection.	Vergori A et al.	2020	Le infezioni in medicina
33482747	Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.	Grzegorzewska AE et al.	2021	BMC infectious diseases
33519226	Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.	Fernandes MR et al.	2021	Pharmacogenomics and personalized medicine
33612760	Interferon-γ inducible protein-10 and interleukin 28B gene polymorphism as predictive markers for genotype 4 hepatitis C virus treatment response.	Abd El-Maksoud E et al.	2020	Tropical biomedicine
33841497	Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population.	Fu Z et al.	2021	Frontiers in genetics
34307188	Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.	da Silva AMV et al.	2021	Frontiers in cellular and infection microbiology
34307418	Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis.	Ying SY et al.	2021	Frontiers in medicine
34416803	[Investigation of the Relationship Between IL28B Polymorphisms and Plasma IL28B Levels in Patients with Chronic Hepatitis B or C].	Koç Kuralay Z et al.	2021	Mikrobiyoloji bulteni
34775984	The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients.	Rahimi P et al.	2021	Virology journal
34835060	Association between Maternal Non-Coding Interferon-λ Polymorphisms and Congenital Zika Syndrome in a Cohort from Brazilian Northeast.	Rossi ÁD et al.	2021	Viruses
35118914	Association between Psoriasis Disease and IFN-λ Gene Polymorphisms.	Yilmaz B et al.	2022	Immunological investigations
35784542	Favorable Genotypes of Type III Interferon Confer Risk of Dyslipidemia in the Population With Obesity.	Xu T et al.	2022	Frontiers in endocrinology
35987511	Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity.	Gupta K et al.	2022	Gene
36164570	Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.	Alshabeeb MA et al.	2022	Saudi pharmaceutical journal
36323460	Respiratory syncytial virus: host genetic susceptibility and factors associated with disease severity in a cohort of pediatric patients.	I G Giamberardino H et al.	2022	Journal of tropical pediatrics
36335097	Analysis of clinically relevant variants from ancestrally diverse Asian genomes.	Chan SH et al.	2022	Nature communications
36353205	Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment.	Yin GQ et al.	2022	World journal of gastroenterology
36387492	Gene variants in pro-coagulant and anti-coagulant genes could be prognostic genetic markers of COVID-19 susceptibility.	Srivastava S et al.	2022	Heliyon
37101651	Gene polymorphisms of inflammatory factors in liver cirrhosis.	Xiao S et al.	2023	Frontiers in genetics
38003018	Variants of IFNL4 Gene in Amazonian and Northern Brazilian Populations.	Angelim CC et al.	2023	Genes

The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.

Genome context:

Select flank length:

Genomic regions, transcripts, and products
Top▲ Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.

Choose placement

dbSNP Short Genetic Variations

Welcome to the Reference SNP (rs) Report

Reference SNP (rs) Report

rs8099917